Enanta Pharmaceuticals Inc. has announced a new immunology program and updated progress in its immunology pipeline. The company’s new program is focused on developing oral MRGPRX2 inhibitors for type 2 immune driven diseases, with an initial focus on chronic spontaneous urticaria and other mast cell-driven diseases.
Arcus Biosciences Inc. has announced five new research programs for autoimmune and inflammatory diseases, and is targeting initiation of the first clinical studies next year.
